Pfizer Inc says its experimental COVID-19 vaccine is more than 90 percent effective, a major victory in the fight against a pandemic that has killed more than a million people, battered the world’s economy, and upended daily life.
Pfizer and German partner BioNTech SE are the first drugmakers to release successful data from a large-scale clinical trial of a coronavirus vaccine. The companies said they have so far found no serious safety concerns and expect to seek US authorisation this month for emergency use of the vaccine for people aged 16 to 85.
Keep readinglist of 4 items
If authorised, the number of doses will initially be limited and many questions remain, including how long the vaccine will provide protection. However, the news provides hope that other COVID-19 vaccines in development may also prove effective.
“Today is a great day for science and humanity,” Albert Bourla, Pfizer’s chairman and chief executive, said.
“We are reaching this critical milestone in our vaccine development programme at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen.”
For Pfizer to seek US authorisation for emergency use of its vaccine, it will need two months of safety data from about half the study’s 44,000 participants, which is expected late this month.
The MSCI index of world stock markets hit a record high following the announcement. Pfizer shares were indicated 6 percent higher in New York, while BioNTech’s US stock leapt 18 percent.
“I’m near ecstatic,” Bill Gruber, one of Pfizer’s top vaccine scientists, said in an interview. “This is a great day for public health and for the potential to get us all out of the circumstances we’re now in.”
1.3 billion doses
Gloria Taliani, professor of Infectious Diseases at the Sapienza University of Rome, Italy, called the result an “incredible breakthrough” as she had been expecting the vaccine to be effective in just 75 percent of the subjects.
The next steps, Taliani explained to Al Jazeera, will consist in examining “who received the vaccine during the first trial in order to extend it to other populations which are much more in need to be vaccinated,” including older people and those with other coexisting diseases who were “probably not included in the first trial.”
“But the unanswered question is, how much will it cost? And how less rich countries will be able to afford it?,” she added.
Pfizer and BioNTech have a $1.95bn contract with the US government to deliver 100 million vaccine doses beginning this year. They have also reached supply agreements with the European Union, the United Kingdom, Canada and Japan.
To save time, the companies began manufacturing the vaccine before they knew whether it would be effective. They now expect to produce up to 50 million doses, or enough to protect 25 million people this year.
Pfizer said it expects to produce up to 1.3 billion doses of the vaccine in 2021.
The US pharmaceutical giant said the interim analysis was conducted after 94 participants in the trial developed COVID-19, examining how many of them had received the vaccine versus a placebo.
The company did not break down exactly how many of those who fell ill received the vaccine. Still, more than 90 percent effectiveness implies that no more than eight of the 94 people who caught COVID-19 had been given the vaccine, which was administered in two shots about three weeks apart.
The efficacy rate is well above the 50-percent effectiveness required by the US Food and Drug Administration for a coronavirus vaccine.
To confirm the efficacy rate, Pfizer said it would continue the trial until there are 164 COVID-19 cases among participants. Given the recent spike in US infection rates, that number could be reached by early December, Gruber said.
The data have yet to be peer-reviewed or published in a medical journal. Pfizer said it would do so once it has results from the entire trial.
The global race for a vaccine has seen wealthier countries forge multibillion-dollar supply deals with drugmakers like Pfizer, AstraZeneca Plc and Johnson & Johnson, raising questions over when middle income and poorer nations will get access to inoculations.
The US’s quest for a vaccine has been the Trump administration’s central response to the pandemic. The US has the world’s highest known number of COVID-19 cases and deaths, with more than 10 million infections and more than 237,000 fatalities.
President Donald Trump repeatedly assured the public that his administration would likely identify a successful vaccine in time for the presidential election, held last Tuesday. On Saturday, Democratic rival Joe Biden was declared the winner.
Vaccines are seen as essential tools to help end the health crisis that has shuttered businesses and left millions out of work. Millions of children whose schools were closed in March remain in remote learning programmes.
Dozens of drugmakers and research groups around the globe have been racing to develop vaccines against COVID-19, which on Sunday exceeded 50 million infections since the new coronavirus was first recorded late last year in China.